Inmazeb™ (atoltivimab/maftivimab/odesivimab-ebgn) – New orphan drug approval
October 14, 2020 - The FDA announced the approval of Regeneron’s Inmazeb (atoltivimab/maftivimab/odesivimab-ebgn), for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection.
Top